yocardial flow reserve (MFR) is defined as the ratio of maximal to basal myocardial blood flow (MBF), and it is related to the severity of coronary artery stenosis. 1-8 Therefore, the MFR value is clinically useful for decision-making and the strategy of coronary intervention. Recent studies have shown that MFR is impaired by age 9 and coronary risk factors, such as smoking, 10 hyperlipidemia (HPL), 11,12 diabetes mellitus (DM), 13 and hypertension (HTN), 14 even in the absence of coronary stenosis. The MFR can be accurately measured invasively and noninvasively. Clinical evaluation of MFR using positron emission tomography (PET) is a safe and repeatable method to use for patients without coronary artery dis-ease, 15-17 compared with invasive methods such as Doppler flow-wire. 18 Several studies have reported that MFR is impaired, together with the poor prognosis, in both patients with dilated cardiomyopathy (DCM) 19-24 and those with hypertrophic cardiomyopathy (HCM). [25] [26] [27] [28] [29] [30] In particular, the prognosis is poorer for patients with the dilated phase of HCM (DHCM), who have systolic dysfunction and left ventricular (LV) remodeling, than in those with DCM. However, the pathophysiological differences between these 2 types of cardiomyopathies remain unclear. The purpose of this study was to compare MBF, MFR and coronary vascular resistance (CVR) between patients with DCM and those with DHCM, using 15 O-labeled water PET, 8, [31] [32] [33] which is similar to 13 N ammonia PET. 34
they underwent PET study, cardiac catheterization, and sampling of blood at least 2 weeks after stabilization of heart failure. The patients in Group A satisfied the following inclusion criteria: [1] ECG abnormalities, [2] absence of significant coronary stenosis, [3] abnormal LV function by left ventriculography (reduced LV ejection fraction (LVEF, <50%), and dilation), [4] exclusion of other cardiac and systemic disorders. The patients in Group B had: [1] history of HCM without wall motion abnormality and dilation, [2] absence of significant coronary stenosis, and [3] abnormal LV function by left ventriculography (LVEF <50% and dilation). We used the data for normal controls recently reported by Kubo et al 35 from our institution. Ten normal males (Group C) (mean age 31±6 years) were studied to determine control values for MBF and CVR at rest and with pharmacological stress, and to calculate the MFR. None of the normal controls had symptoms of suspected heart disease, a history of prior cardiac events or were smokers. All of them had a normal physical examination, normal resting ECG and chest roentgenography, and no coronary risk factors at the time of medical examination. Thus all had a low probability for heart disease. Each subject gave written informed consent approved by the Kyoto University Ethics Committee.
Study Protocol
Clinical and Functional Evaluation Clinical evaluation (ie, age, gender, and coronary risk factors such as HTN, HPL, obesity, DM, and smoking) was performed on the day of admission. Each medical therapy on the day before the PET study, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor blockers, amiodarone, -blockers, calcium channel blockers, diuretics, digitalis, and nitrate, was recorded. New York Heart Association (NYHA) class and blood chemistry data (brain natriuretic peptide (BNP), total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol, triglycerides (TG), fasting plasma blood sugar concentration, and hemoglobin A1c) were evaluated on the same day as the PET study. To evaluate cardiac function and hemodynamics, each patient underwent right and left heart catheterization, coronary angiography, and left ventriculography within 3 days before or after the PET study (pulmonary capillary wedge pressure (PCWP), cardiac index (CI), LV end diastolic pressure (LVEDP), LVEF, LV end diastolic volume (LVEDV), and LV end systolic volume (LVESV)).
Protocol of the PET Study PET studies were performed at least 2 weeks after stabilization of heart failure and medical therapy. All patients were studied in the absence of any medical therapy after an overnight fast. Caffeine, theophylline, and theophylline derivatives were withdrawn 24 h before imaging. Each subject was positioned in the gantry of the PET camera (Advance, GE Medical Systems, Milwaukee, WI, USA). The spatial resolution of the reconstructed clinical PET images was ~8 mm in full-width half-maximum at the center of the field of view, and the axial resolution was ~4 mm. 36 The subjects lay supine in the PET scanner with their arms out of the field of view. A 10-min transmission scan using 2 rotating 68 Ge pin sources made the attenuation correction. After each transmission, subjects were asked to inhale oxygen-15-labeled carbon monoxide ([ 15 O]CO) for 2 min. After inhalation, the [ 15 O]CO was allowed to combine with hemoglobin in the red blood cells for 3 min before a 4-min static scan was started. During the scan period, 3 blood samples were drawn at 2-min intervals and the radioactivity was measured. In the resting condition, approximately 740 MBq of [ 15 O]H2O was injected intravenously over 2 min and the 20-frame dynamic PET scan was performed for 6 min. Ten minutes later, after physical decay of the 15 O activity to nearly undetectable levels, ATP was infused intravenously for 9 min at a constant rate of 0.16 mg· kg -1 · min -1 . 31, 37 Three minutes after the start of the ATP infusion, [ 15 O]H2O was administered again and the second set of dynamic PET images was acquired. Heart rate (HR), blood pressure and ECG were monitored continuously during the PET studies. Each patient and normal control was carefully monitored and questioned during and after termination of the pharmacologic agent infusion to determine any occurrence of (Fig 2) . The arterial input function was obtained from the LV time -activity curve using a validated method in which corrections were made for the limited recovery of the LV ROI and the spillover from myocardial activities. 32 MBF, MFR and CVR MBF values (ml·min -1 ·g -1 ) were calculated according to a previously published method using the single-compartment model, which is theoretically free from partial volume effects or wall motion. 32, 33, 38 MFR was calculated as the ratio of stimulated flow to resting flow. An index of CVR was derived from the ratio of mean arterial blood pressure (mmHg) to MBF (ml·min -1 ·g -1 ).
Statistical Analysis
Statistical analysis was performed with a commercially available personal computer software program (Stat View-J 5.0, SAS Institute Inc, Cary, NC, USA). Values of each parameter are expressed as mean values ± SD. Statistical analyses of age, NYHA, the results of cardiac catheterization and blood samples was performed by unpaired t-test. For gender and coronary risk factors, Fisher's exact probability test was performed. Student-Newman-Keuls test was used to analyze MBF, MFR, and CVR. Probability values of less than 0.05 were considered statistically significant.
Results

Patients' Clinical and Functional Characteristics
The clinical characteristics of patients are summarized in Table 1 . There were no significant differences in age, gender, or NYHA functional class between Groups A and B. Although the prevalences of HTN, HPL, obesity, DM, and smoking were slightly higher in Group B, they did not achieve statistical significance. Medications in each group were not statistically different. Among the blood chemistry data, only the plasma HDL-C level in Group A was statistically higher than that for Group B (50±13 vs 38±8 mg/dl; p<0.05). Table 2 shows the cardiac functional characteristics of the study patients. Systolic and diastolic blood pressures (SBP and DBP), HR, PCWP, CI, and LVEDP were not statistically different between the 2 groups. Indexes derived from left ventriculography, such as LVEF, LVEDV, and LVESV, were comparable between the 2 groups. Two of 7 patients with DHCM had an apparent family history of HCM (confirmed by serial clinical tests such as echocardiography).
PET Study MBF at Rest and During ATP Infusion
The MBF values at rest and during ATP infusion in the DCM (Group A) and DHCM (Group B) groups and normal controls (Group C) are shown in Fig 3. In this study, the pressurerate products (HR (beats/min) × SBP (mmHg)) did not differ between Groups A and B, not only at rest (Group A vs Group B =72.1±14.7 (×10 3 ) vs 73.0±21.5, NS), but also during ATP infusion (Group A vs Group B =63.6±10.4 (×10 3 ) vs 67.2±10.9, NS). The MBF at rest was slightly lower in Group B than in Group A, but there was no significant difference between the 2 groups (Group A vs Group B =0.66±0.20 vs 0.49±0.05 ml·min -1 ·g -1 , NS). The MBF in Group B was significantly lower than in Group C (Group B vs Group C =0.49±0.05 vs 0.79±0.29 ml·min -1 ·g -1 , p= 0.011). The MBF during ATP infusion was significantly lower in Group B than in Group A (Group A vs Group B = 1.67±0.73 vs 0.73±0.11 ml· min -1 · g -1 , p=0.0038). These values in both Group A and Group B were significantly lower than in Group C (Group C =3.70±0.67 ml·min -1 ·g -1 , Group A vs Group C, p=0.00012, Group B vs Group C, p=0.00013). No adverse events, such as complete AV block, occurred in any subject during ATP infusion.
MFR (Fig 4) The MFR value in each group was 2.62±1.08 (Group A), 1.49±0.31 (Group B) and 5.16±1.64 (Group C). The MFR values in Groups A and B were significantly lower than that in Group C (Group A vs Group C, p=0.00015, Group B vs Group C, p=0.00013). Furthermore, the MFR in Group B was significantly lower than that in Group A (p=0.042), whereas pressure -rate products at rest and during ATP infusion did not differ between the 2 groups.
CVR CVR values at rest and during ATP infusion in each group are shown in Fig 5. The CVR value at rest in each group was 141±49 (Group A), 171±29 (Group B) and 100±26 (Group C) mmHg/[ml·min -1 ·g -1 ]. The CVR at rest in the normal controls (Group C) was significantly lower than that in Groups A and B (Group A vs Group C, p=0.039, Group B vs Group C, p=0.0019), but there was no significant difference between Groups A and B. On the other hand, the CVR during ATP infusion in Group B was significantly higher than in Group A (Group A vs Group B =56±25 vs 111±24, p=0.00012). The CVR during ATP infusion in Group C was significantly lower than in each cardiomyopathy group (Group A vs Group C =56±25 vs 20±5, p=0.00083, Group B vs Group C =111±24 vs 20±5, p=0.00013).
Regional Differences in MFR The regional differences in MFR in patients with DCM and DHCM were evaluated using the same method as previously reported. 35, 36 The MFR in the septum was lower than that in the free wall in patients with DHCM, but this difference did not achieve 
Discussion
This study elucidated the differences in MBF and MFR between patients with DCM and those with DHCM, although there were no significant differences in the clinical and hemodynamic parameters of the 2 groups, apart from plasma HDL-C concentration. The MBF during ATP infusion and MFR in patients with DHCM were significantly lower than in those with DCM, although MBF at rest did not differ significantly. The CVR under ATP infusion in patients with DHCM was significantly higher than in the DCM group, but CVR at rest did not differ between the 2 groups. These findings demonstrate that impaired vasodilatation capacity (ie, dysfunction of the microcirculation) is more severe in patients with DHCM than in patients with DCM.
Difference in the Impairment of Vasodilatation Capacity
Our results indicate that MFR in patients with DHCM is significantly lower than in those with DCM and 2 factors may explain this. The first is epicardial coronary stenosis [1] [2] [3] [4] [5] [6] [7] [8] and the second is disturbance of the microcirculation. [9] [10] [11] [12] [13] [14] In this study, all patients underwent coronary angiography and the absence of angiographically significant coronary stenosis was verified. Therefore, the difference in impaired vasodilatation capacity may be related to functional differences in the microcirculation. Impaired microcirculation without epicardial stenosis is related to age, 9 coronary risk factors (such as smoking, 10 HPL, 11,12 DM 13 and HTN 14 ), medications, 14 and small-vessel disease. 27, 28 In the present study there were no significant differences between the 2 groups in age, coronary risk factors, functional states (NHYA class and the value of BNP), or medications, except for HDL-C concentration. Therefore, in the present study these factors were not responsible for the differences in microcirculation because the specific correlation between HDL-C concentration and MFR has not been previously reported. Recent studies have demonstrated that impaired microcirculation in patients with HCM is related to abnormalities in the intramural small arteries. 27, 28 In an autopsy study Kawai and Fujiwara also noticed marked narrowing of these vessels in patients with DHCM. 39 In contrast to those findings, changes in the small arteries were absent in patients with DCM. 22 Although myocardial biopsy was not performed in all patients in the present study, because of procedural risk, the difference in the MFR between these 2 types of cardiomyopathies may be attributed to dysfunction of the intra-myocardial small arteries. Also, this study demonstrated that the MFR in the septum was lower than that in the free wall in patients with DHCM, though the septal MFR was higher than in that of the free wall in patients with DCM. These results indicate that the differences in the MFR in these 2 types of cardiomyopathies might be caused not only by dysfunction of the intra-myocardial small arteries, 22, 27, 28, 39, 45 but also by septal hypertrophy and/or deterioration of myocardial relaxation. However, the details concerning the difference still remain unclear. Further studies are necessary to elucidate this point.
DHCM
In patients with HCM, LV systolic function is usually normal or supernormal. However, a few patients with HCM have been reported to progress to a state that is characterized by systolic dysfunction and LV dilation and resembles DCM. [39] [40] [41] [42] [43] [44] [45] This particular progressive change in HCM is known as DHCM, the endstage or burn out of HCM. The prognosis in patients with DHCM is very poor because their heart failure condition is severe and there is no evidence that medical therapies such as ACE inhibitors or -blockers can improve ventricular systolic dysfunction and the heart failure. Earlier studies have reported that narrowing of the intra-myocardial small artery is present in patients with DHCM 39, 45 and this might lead to the progressive change in systolic dysfunction and LV dilation. In order to evaluate myocardial impairment, in our study, approximately half of the patients underwent cardiac magnetic resonance imaging (DCM: 10, DHCM: 4). Late gadolinium enhancement was observed in 4 of the 10 patients with DCM and in all patients with DHCM, and the extent of enhancement in DHCM was more severe than in DCM. Moon et al have reported that late gadolinium enhancement in patients with cardiomyopathy is related to myocardial collagen volume, which is a major component of myocardial fibrosis. 46 Ohtani et al have also indicated a higher prevalence of myocardial fibrosis in DHCM than in DCM. 47 Although it is unclear whether narrowing of the intra-myocardial small arteries or myocardial fibrosis occurs first, ischemic damage from the narrowing of the vessels might cause myocardial fibrosis. The reduction in MFR (ie, impaired microcirculation) that we demonstrated in this study lends support to the aforementioned speculation. Thus, dysfunction of the microcirculation in patients with DHCM may lead to the progressive change from HCM to DHCM, and irreversible cardiac dysfunction with poor prognosis.
Study Limitations
First, the number of patients with DHCM was small. It is difficult to detect the progression from HCM to DHCM, because it can not be detected unless serial echocardiographic studies are performed frequently and routinely. Second, the mean age of the control subjects did not match that of the patients with cardiomyopathies. MFR is largely influenced by age, 9 but the main purpose of this study was to compare the MFR between DCM and DHCM, and the influence of aging on MFR was relatively small compared with the approximately 50-79% difference in MFR between the patients and the normal controls (27% reduction in MFR in the older people compared with the young 9 ). Third, the plasma HDL-C level was significantly different between the 2 types of cardiomyopathies. The plasma levels of TC and TG have been reported to correlate with MFR, 11, 12 but there is no evidence concerning the relationship between MFR and HDL-C. Finally, a comparison of patients with HCM and those with DHCM was not performed in this study, nor were serial changes of MFR from HCM to DHCM investigated. It is true that the mechanism of the progressive change from HCM to DHCM is an important subject, but it may be impossible to clarify the borderline of these 2 diseases. Further studies are necessary to elucidate this point.
Conclusions
This study demonstrates that MFR in patients with DHCM is significantly lower than in patients with DCM, even when the patients' clinical characteristics and hemodynamic parameters do not differ. These results indicate that impaired vasodilatation capacity (ie, dysfunction of the microcirculation) in patients with DHCM is more severe than in patients with DCM, suggesting that the reduction in MFR might account for the higher rate of cardiac events and poorer prognosis in patients with DHCM compared with those with DCM.
